NCT05837052招募中2 期
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Treatment for Patients With Stage IIIB-IVA Oligometastatic Non-small Cell Lung Cancer
Zhejiang University1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2023年5月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- the rate of NSCLC converting to resectable tumors
研究概览
简要总结
This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
详细描述
This single-arm, open-label, prospective phase II clinical trial was designed to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
The primary endpoints were the rate of NSCLC converting to resectable tumors and the 1-year progression-free survival (PFS) rate.The secondary endpoints included the rates of R0 resection, major pathological response (MPR) and pathological complete response (pCR), overall survival (OS) and PFS. Multi-omics analysis will be performed to identify potential biomarkers for treatment response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients should voluntarily join this study and sign the informed consent form
- •NSCLC patients diagnosed by cytology or histology and not previously receiving anti-tumor treatments (including systemic treatments, local treatments .etc)
- •Patients with IIIB - IVA oligometastatic NSCLC : (a) IIIB - IIIC stage (T1-4N2-3): patients are not suitable or refuse to receive upfront surgical resection or radiotherapy; (b) oligometastatic stage IV (T1-3N0-2): radical resection/radiotherapy is feasible for metastatic lesions (the number of metastases being up to 3, and the maximum diameter of metastases being up to 2cm)
- •After evaluation by MDT, upfront surgical resection is not the preferred treatment, but after induction systemic treatments, radical resection of the primary tumor is feasible, and radical resection/radiotherapy is feasible for extrathoracic metastases (if any)
- •Age from 18 to 75 years old, both male and female
- •ECOG score 0-1
- •According to the RECIST v1.1 , patients should have at least one measurable lesion
- •For suspicious mediastinal lymph nodes (including pathological enlargement or PET-CT indicating malignancy, etc.), further sampling is required for pathological diagnosis by EUBS, thoracoscopy, or mediastinoscopy
- •According clinical evaluation, the lung function of patients (such as FVC, FEV1, TLC, FRC, DLco, etc.) should be sufficient for pneumonectomy
- •The function of important organs should meet the following requirements: absolute count of neutrophils ≥ 1.5 × 109/L； Platelets ≥ 100 × 109/L； Hemoglobin ≥ 90g/L; Serum albumin ≥ 35g/L; Thyroid hormone (TSH) ≤ 1 × ULN； Serum bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 3 × ULN； International standardized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN； Serum creatinine ≤ 1.5 × ULN
- •Female patients at childbearing age are required to use contraceptive measures; for male patients whose partners are women at childbearing age, effective methods of contraception should be used during the trial period
排除标准
- •Patients who meet any of the following conditions will not be enrolled in this study:
- •NSCLC patients have sensitive EGFR mutation, EML4-ALK fusion or other forms of ALK gene changes
- •Patients have previously received immune checkpoint inhibitors such as PD-1/ PD-L1/CTLA4 antibody
- •Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)
- •Patients with active hepatitis B/C
- •Patients with any active autoimmune diseases or a history of autoimmune diseases
- •Patients who are using immunosuppressive agents or require systemic hormone therapy
- •Patients with hypertension but without good control even through antihypertensive medication treatment ; patients with clinical symptoms or diseases related to unsatisfying cardiac function
- •Patients with abnormal coagulation function (INR>2.0, PT>16s)
- •Arterial/venous thrombotic events occurred before screening within 6 months
- •Patients with active infection
- •Patients with congenital or acquired immune dysfunction (such as HIV infection)
- •According to the judgment of the researchers, patients have other factors that may affect the results of the research or cause the research to be terminated
结局指标
主要结局
the rate of NSCLC converting to resectable tumors
时间窗: up to 16 weeks
the proportion of unresectable NSCLC patients who are converted to being suitable for radical pneumonectomy after 3-4 cycles serplulimab plus chemotherapy
the 1-year progression-free survival (PFS) rate
时间窗: up to one year
the proportion of patients who are progression-free after pneumonectomy
次要结局
- the rate of pathological complete response (pCR)(up to 16 weeks)
- the rate of R0 resection(immediately after the surgery)
- Progression-free survival (PFS)(up to five years)
- Overall survival (OS)(up to five years)
- the rate of major pathological response (MPR)(up to 16 weeks)
研究者
Weijia Fang, MD
Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.PDL1 Gene MutationNon-small Cell Lung CancerNCT06195683Zhejiang Cancer Hospital23
进行中（未招募）
2 期
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyAdvanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT05585580Qilu Hospital of Shandong University59
招募中
2 期
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCCarcinoma, Non-Small-Cell LungNCT05940532Hunan Cancer Hospital41
进行中（未招募）
2 期
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric JunctionStomach NeoplasmsImmune Checkpoint InhibitorsNCT06576921Xijing Hospital116
进行中（未招募）
2 期
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After TreatmentSmall-cell Lung CancerNCT05957510Guangdong Association of Clinical Trials66